603858.SHG Shandong Buchang Pharmaceuticals Co Ltd
- Market cap
- CNY 15.9B
- P/E
- 54.0x
- P/B
- 1.58x
- ROE
- 10.2%
- Dividend yield
- 3.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603858.SHG undervalued?
Graham number603858.SHG trades 94.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Buchang Pharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Shandong Buchang Pharmaceuticals Co Ltd yet.
Shandong Buchang Pharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China and internationally. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
Full company profileShandong Buchang Pharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Buchang Pharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.3B | 13.9B | 13.7B | 14.3B | 16.0B | 15.8B | 15.0B | 13.2B | 11.0B | 11.9B | 10.7B |
| Gross Profit | 10.2B | 11.4B | 11.3B | 11.9B | 12.3B | 11.6B | 10.7B | 8.92B | 6.45B | 7.48B | 6.43B |
| Operating Income | 1.97B | 1.76B | 2.27B | 2.43B | 2.37B | 1.75B | -1.25B | 436M | -247M | 1.48B | 1.50B |
| EBITDA | 2.30B | 2.02B | 2.19B | 2.66B | 2.71B | 2.23B | 2.26B | 1.61B | 1.12B | 1.17B | 1.37B |
| Net Income | 1.77B | 1.64B | 1.89B | 1.95B | 1.86B | 1.29B | -1.53B | 319M | -554M | 361M | 1.05B |
| EPS | 1.69 | 1.42 | 1.65 | 1.74 | 1.68 | 1.17 | -1.38 | 0.29 | -0.51 | 0.34 | 1.00 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7B | 19.2B | 20.0B | 21.2B | 22.9B | 24.0B | 22.0B | 20.9B | 19.3B | 19.2B | 19.1B |
| Total Liabilities | 5.96B | 5.98B | 6.17B | 7.40B | 9.08B | 9.54B | 9.68B | 9.52B | 9.52B | 9.81B | 9.39B |
| Shareholders' Equity | 12.6B | 13.1B | 13.7B | 13.6B | 13.7B | 14.4B | 12.4B | 11.6B | 10.2B | 10.0B | 10.3B |
| Cash & Short-term Investments | 3.81B | 2.17B | 1.69B | 2.22B | 1.86B | 1.72B | 2.88B | 1.05B | 1.22B | 1.22B | 1.34B |
| Total Debt | 6.00M | 1.80B | 2.25B | 2.72B | 3.45B | 3.54B | 3.15B | 2.35B | 2.47B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.67B | 1.96B | 2.05B | 2.62B | 1.96B | 1.32B | 2.76B | -164M | 940M | 1.16B | - |
| Capital Expenditure | 678M | 1.46B | 1.31B | 662M | 536M | 434M | 543M | 530M | 197M | 123M | 211M |
| Free Cash Flow | 991M | 507M | 741M | 1.96B | 1.42B | 887M | 2.21B | -726M | 743M | 1.03B | 482M |
| Ratios | |||||||||||
| ROE | 14.0% | 12.5% | 13.7% | 14.3% | 13.6% | 8.9% | -12.4% | 2.7% | -5.4% | 3.6% | 10.2% |
| ROA | 9.5% | 8.5% | 9.4% | 9.2% | 8.1% | 5.4% | -7.0% | 1.5% | -2.9% | 1.9% | 5.5% |
| Net Profit Margin | 14.4% | 11.8% | 13.8% | 13.7% | 11.6% | 8.2% | -10.2% | 2.4% | -5.0% | 3.0% | 9.8% |
| Debt to Equity | 0.00x | 0.14x | 0.16x | 0.20x | 0.25x | 0.25x | 0.26x | 0.20x | 0.24x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Buchang Pharmaceuticals Co Ltd dividends
- Dividend yield
- 3.33%
- Forward dividend
- -
- Payout ratio
- 147.1%
- Ex-dividend date
- Nov 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 531M | 0.50 | 147.1% |
| 2024 | CNY 272M | 0.25 | - |
| 2023 | CNY 1.19B | 1.08 | 374.4% |
| 2022 | CNY 398M | 0.36 | - |
| 2021 | CNY 582M | 0.53 | 45.1% |
| 2020 | CNY 1.79B | 1.61 | 95.9% |
| 2019 | CNY 1.37B | 1.23 | 70.6% |
| 2018 | CNY 1.19B | 1.04 | 62.8% |
| 2017 | CNY 1.17B | 1.01 | 71.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Aug 19, 2019.
Who owns Shandong Buchang Pharmaceuticals Co Ltd
- Insiders 62.56%
- Institutions 4.20%
- Public & others 33.24%
- Shares outstanding 1.05B
- Free float 378M
Shandong Buchang Pharmaceuticals Co Ltd company profile
- Company name
- Shandong Buchang Pharmaceuticals Co Ltd
- Ticker
- 603858.SHG
- ISIN
- CNE100002FV6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,237
- Fiscal year end
- December
- Address
- No. 369 Zhonghua West Road, Heze, China, 274000
- Phone
- 86 53 0529 9167
- Website
- buchang.com
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China and internationally. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
Shandong Buchang Pharmaceuticals Co Ltd management
10- Mr. Chao ZhaoPresident · born 1967
- Mr. Yi Min WangExecutive VP & Vice Chairman · born 1961
- Mr. Xiaogang ZhaoChief Financial Officer · born 1979
- Mr. Ren Hui XueVP of Marketing & Director · born 1968
- Ms. Xin WangDirector & Secretary · born 1979
- Dr. Zhao Buchang M.D.Founder
- Kai ChengAccounting Supervisor
- Mr. Wei Jun LiVice President of Administration & Human Resources · born 1963
- Haiqin WuChairman of the Academic Committee
- Ms. Wei ZhaoVice President of Procument